Shenzhen Okejian Biopharmaceutical Technology

Shenzhen Okejian Biopharmaceutical Technology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of long-acting recombinant protein drugs. The company utilizes its proprietary human serum albumin (HSA) fusion technology platform to extend the half-life and improve the pharmacokinetic profiles of therapeutic proteins. Its pipeline includes several innovative fusion proteins targeting viral infections, metabolic diseases, and oncology, with its lead candidate OKJ-101 undergoing clinical trials for chronic hepatitis. Okejian aims to provide more convenient and effective treatment options by significantly reducing dosing frequency for patients with chronic conditions. The company is supported by prominent Chinese venture capital firms and focuses on the bio-better segment of the pharmaceutical market.